Recently, E-nitiate Biopharmaceuticals (Hangzhou) Co.,Ltd. (hereinafter referred to as "E-nitiate Biopharmaceuticals") announced that the first dose of QY201 was given to 3 subjects in a phase 1 study. QY201 is an innovative drug for the treatment of atopic dermatitis developed independently by E-nitiate Biopharmaceuticals

This study was a single-center, randomized, double-blind, placebo-controlled, dose-increasing experiment to study the effects of single dose, multiple dose and food on pharmacokinetics of QY201. The PI was Professor Ruan Zou Rong from the Clinical Pharmacology Center of the Second Affiliated Hospital of Zhejiang University School of Medicine. The study was designed to evaluate the tolerance, pharmacokinetic characteristics and the effect of food on the pharmacokinetics of QY201 tablets in healthy subjects.

Ding Shizhe, general manager of E-nitiate Biopharmaceuticals, said that it took only one month for the company to successfully complete the enrollment and administration of subjects from the receipt of the notice of approval for drug clinical trial. The progress was very fast and the efficiency was very high thanks to the hard work of our team, the support and cooperation of the strategic partner Betta Pharmaceuticals team, and the professional guidance of PI organization. At present, there are still huge unmet clinical needs in the field of dermatology, and safer and more effective drugs are needed to solve the problems of patients with dermatosis. The clinical research will be promoted quickly and we strive to push QY201 to marketization as soon as possible.

QY201 was independently developed by E-nitiate with global patents, is undergoing phase I clinical trial for atopic dermatitis. QY201 acts on Jak1/Tyk2 dual targets with higher activity and selectivity, which is significantly superior to the similar drugs. Other pipelines, such as QY101, QY211, QY301, are also about to enter the clinical stage.

E-nitiate Biopharmaceuticals (Hangzhou) Co.,Ltd, founded in 2020 by VivaVision Biotech and Betta fund, is a key introduction project of Linping National Development Zone. The company is committed to becoming a leader in the development of new drugs to fulfill the unmet clinical needs for autoimmune diseases. QY201,QY101,QY211 and QY301, a class of innovative drugs with global patents, have entered or will enter the clinical stage. As Dr. Shen Wang, a senior medicinal chemist as the core, the team members used to worked in many well-known pharmaceutical enterprises such as Amgen, Johnson & Johnson and Merck, and possess first-class drug R&D and industrialization abilities. The company is an innovative pharmaceutical company with great potential.